Professor Jacob George - Westmead Millennium Institute

Sacks R, Davis, Aitken CK, Higgs P, Moneer S, Flynn J, Suppiah V, Tracy L, French R, Bowden S,Drummer H, George J, Bharadwaj M and Hellard M. Hepatitis C virus-specific cellular immunitydoes not protect against future HCV infection in anti-HCV negative injecting drug users. Journalof Hepatology 2012 (Submitted J Hepatology) Pianko S, Zeuzem S, Chuang WL, Foster GR, Sarin SK, Flisiak R, Lee CM, Andreone P, Piratvisuth T,Shah S, Sood A, George J, Gould M, Komolmit G, Thongsawat S, Tanwandee T, Rasenack J, Li Y,Pang M, Yin Y, Feutren G and Jacobson I for the B2202 Study Team. Randomized Trial ofAlbinterferon-Alfa-2b Every Four Weeks for Genotype 2/3 Chronic Hepatitis C. Journal of ViralHepatitis 2012 (Accepted 13/01/2012). Grebely J, Hellard M, Applegate T, Petoumenos K, Yeung B, Marks P, Feld JJ, Rawlinson W, LloydAR, George J, Kaldor JM, Dore GJ, Matthews GV, on behalf of the ATAHC Study Group. Virologicalresponses during treatment for recent hepatitis C virus infection: Potential benefit for the use ofribavirin in HCV/HIV co-infection. AIDS 2012 (E-Pub ahead of print)Ahlenstiel G, Booth DR, George J. Role of direct acting antiviral and IL28B in HCV infection: WillIL28B polymorphisms remain relevant to DAA treatment paradigms? Antiviral Therapy 2012(Accepted in press 23/1/2012) Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V,Booth D, Stewart G, van Bömmel F, Brodzinski A, Fülöp B, Migaud P, Berg T. Combined effects ofdifferent IL28B gene variants on the outcome of dual combination therapy in chronic HCV type 1infection. Journal of Hepatology 2012 (E-Pub ahead of print)Barrera F, Douglas M, George J. Management of Insulin Resistance and Type 2 DiabetesAssociated with Hepatitis C Virus Infection. Hot Topics in Viral Hepatitis 2012 (Accepted01/02/2012)Mahady SE, George J. Management of Non-Alcoholic Steatohepatitis – An Evidence BasedApproach. Clinics of Liver Disease 2012 (Accepted 01/02/2012)Keating SE, Hackett DA, George J, Johnson NA. Exercise and Non-Alcoholic Fatty Liver Disease: ASystematic Review and Meta-Analysis. Journal of Hepatology 2012 (E-pub ahead of print20/02/12)Vongsuvanh R, George J, McLeod D, van der Poorten D. Visceral Adiposity Index Is not APredictor of Liver Histology in Patients with Non-Alcoholic Fatty Liver Disease. Journal ofHepatology 2012 (E-Pub ahead of print, 17/4/2012). Gidding HF, Law MG, Amin J, Ostapowicz G, Weltman M, Macdonald GA, Sasadeusz JJ, Haber P,George J, Dore GJ. Hepatitis C Treatment Outcomes in Australian Clinics. Medical Journal ofAustralia 2012 (In press, Accepted 24/2/12).Nguyen V, George J, van der Poorten D. A Maxillary Mass in a HBV-Cirrhotic Patient. LiverInternational 2012 (E-Pub ahead of print, 1/3/2012).Keating SE, Hackett DA. George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: asystematic review and meta-analysis. Journal of Hepatology 2012 (E-Pub ahead of print 2012).Thein HH, Walter S, Gidding H, Amin J, Law M, George J, Dore G. Survival after diagnosis ofhepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort.Hepatology Research 2012 (E-pub ahead of print, 18/4/12).Westmead Millennium Institute

Pianko S, Zeuzem S, Chuang WL, Foster GR, Sarin SK, Flisiak R, Lee CM, Andreone P, Piratvisuth T,Shah S, Sood A, George J, Gould M, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Li Y,Pang M, Yin Y, Feutren G, Jacobson IM for the B2202 Study Team. Randomized trial ofalbinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. Journal of ViralHepatitis 2012 (In-press, E-Pub ahead of print). Mahady S, George J. Pioglitazone and Vitamin E for Non-Alcoholic Steatohepatitis – A Cost UtilityAnalysis. Hepatology 2012 (Accepted 29/5/12, In Press).2011Walter, S., Thein, H., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2011), Risk factors forhepatocellular carcinoma in a cohort infected with hepatitis B or hepatitis C. Journal ofgastroenterology and hepatology. 26, 1757-64. [Abstract]Mahady, S., Webster, A., Walker, S., Sanyal, A., George, J. (2011), "The role of thiazolidinedionesin non-alcoholic steatohepatitis- a systematic review and meta analysis". Journal of hepatology.55, 1383-90. [Abstract]Poustchi, H., Farrell, G., Strasser, S., Lee, A., McCaughan, G., George, J. (2011), Feasibility ofconducting a randomised control trial for liver cancer screening: Is a randomized controlled trialfor liver cancer screening feasible or still needed?. Hepatology (Baltimore, Md.). 54, 1998-2004.[Abstract]Bhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J., Saracco, G., Adams, L.,Charatcharoenwitthaya, P., Topping, J., Bugianesi, E., Day, C., George, J. (2011), The naturalhistory of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An internationalcollaborative study. Hepatology (Baltimore, Md.). 54, 1208-16. [Abstract]Adams, L., George, J., Bugianesi, E., Rossi, E., De Boer, W., van der Poorten, D., Ching, H.,Bulsara, M., Jeffrey, G. (2011), Complex non-invasive fibrosis models are more accurate thansimple models in non-alcoholic fatty liver disease. Journal of gastroenterology and hepatology.26, 1536-1543. [Abstract]Suppiah, V., Gaudieri, S., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M.,Spengler, U., Bassendine, M., Dore, G., Irving, W., Powell, E., Hellard, M., Riordan, S., Matthews,G., Sheridan, D., Nattermann, J., Smedile, A., Müller, T., Hammond, E., Dunn, D., Negro, F.,Bochud, P., Mallal, S., Ahlenstiel, G., Stewart, G., George, J., Booth, D., , F. (2011), IL28B, HLA-C,and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection ina European Cohort: A Cross-Sectional Study. PLoS Medicine. 8, e1001092. [Abstract]Park, G., Wiseman, E., George, J., Katelaris, P., Seow, F., Fung, C., Ngu, M. (2011), Non-invasiveEstimation of Liver Fibrosis in Non-alcoholic Fatty Liver Disease Using the (13) C-Caffeine BreathTest. Journal of gastroenterology and hepatology. 26, 1411-6. [Abstract]Thein, H., Walter, S., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2011), Trends inincidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a populationbasedcohort study, 1992-2007. Journal of Viral Hepatitis. 18, e232-e241. [Abstract]Westmead Millennium Institute

Jacobson, I., McHutchison, J., Dusheiko, G., Di Bisceglie, A., Reddy, K., Bzowej, N., Marcellin, P.,Muir, A., Ferenci, P., Flisiak, R., George, J., Rizzetto, M., Shouval, D., Sola, R., Terg, R., Yoshida, E.,Adda, N., Bengtsson, L., Sankoh, A., Kieffer, T., George, S., Kauffman, R., Zeuzem, S., , A. (2011),Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal ofMedicine. 364, 2405-2416. [Abstract]Walter, S., Thein, H., Amin, J., Gidding, H., Ward, K., Law, M., George, J., Dore, G. (2011), Trendsin mortality after diagnosis of hepatitis B or C infection: 1992-2006. Journal of hepatology. 54,879-86. [Abstract] Liu, Y., Brymora, J., Zhang, H., Smith, B., Ramezani-Moghadam, M., George, J., Wang, J. (2011),Leptin and Acetaldehyde Synergistically Promotes ?SMA Expression in Hepatic Stellate Cells byan Interleukin 6-Dependent Mechanism. Alcoholism, clinical and experimental research. 35, 921-8. [Abstract]Patel, K., Jhaveri, R., George, J., Qiang, G., Kenedi, C., Brown, K., Cates, C., Zekry, A., Tillmann, H.,Elliott, L., Kilaru, R., Albrecht, J., Conrad, A., G McHutchison, J. (2011), Open-label, ascendingdose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serumand lipid fractions in patients with chronic hepatitis C. Journal of Viral Hepatitis. 18, 331-337.[Abstract]Gidding, H., Law, M., Amin, J., Macdonald, G., Sasadeusz, J., Jones, T., Strasser, S., George, J.,Dore, G., , T. (2011), Predictors of deferral of treatment for hepatitis C infection in Australianclinics. The Medical Journal of Australia. 194, 398-402. [Abstract]Pattullo, V., Douglas, M., George, J. (2011), Organelle dysfunction in hepatitis C virus-associatedsteatosis: anything to learn from nonalcoholic steatohepatitis?. Expert Review ofGastroenterology & Hepatology. 5, 265-277. [Abstract]Patterson, S., George, J., Strasser, S., Lee, A., Sievert, W., Nicoll, A., Desmond, P., Roberts, S.,Locarnini, S., Bowden, S., Angus, P. (2011), Tenofovir disoproxil fumarate rescue therapyfollowing failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 60, 247-54.[Abstract] Poustchi, H., George, J., Esmaili, S., Esna-Ashari, F., Ardalan, G., Sepanlou, S., Alavian, S. (2011),Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence.PLoS One. 6, e21178. [Abstract]Ahlenstiel, G., Booth, D., George, J. (2011), Clinical significance of IL28B gene variation inhepatitis C virus infection. Hot Topics in Viral Hepatitis. 0, 17-24.Smith, K., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine,M., Matthews, G., Irving, W., Powell, E., Riordan, S., Ahlenstiel, G., Stewart, G., Bahlo, M.,George, J., Booth, D., , T. (2011), Identification of improved IL28B SNPs and haplotypes forprediction of drug response in treatment of hepatitis C using massively parallel sequencing in across-sectional European cohort. Genome medicine. 3, 57. [Abstract]Hebbard, L., George, J. (2011), Animal models of nonalcoholic fatty liver disease. Nature reviews.Gastroenterology & hepatology. 8, 35-44. [Abstract]Hebbard L, George J. Animal Models of Fatty Liver Disease. Nature Reviews Gastroenterologyand Hepatology 2011, Jan;8(1):35-44Westmead Millennium Institute

Poustchi H, George J, Esmaili S, Esna-Ashari F, Ardalan G, Sepanlou SG, Alvarian SM. GenderDifferences of Healthy Ranges for Serum Alanine Aminotransferase Level in Adolescences. PLoSONE 2011;6:e21178.Liu Y, Brymora J, Zhang H, Smith B, Ramezani-Moghadam M, George J, Leptin and acetaldehydesynergistically promotes αSMA expression in hepatic stellate cells by an interleukin 6-dependentmechanism. Alcohol Clinical Experiment Research 2011 May;35:921-8.Park G, Wiseman E, George J, Katelaris PH, Seow F, Fung C, Ngu MC. Non-invasiveEstimation of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Using the 13 C-Caffeine BreathTest. Journal of Gastroenterology and Hepatology 2011;26:1411–1416.Mahady S, Webster A, Walker S, Sanyal A, George J. The role of thiazolidinediones in nonalcoholicsteatohepatitis- a systematic review and meta analysis. Journal of Hepatology2011;55:1383-90.Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA,Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J. The natural history ofnonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborativestudy. Hepatology. 2011;54:1208-16. Matthews GV, Pham ST, Hellard M, Grebely J, Zhang L, Oon A, Marks P, van Beek I, Rawlinson W,Kaldor JM, Lloyd A, Dore GJ, White PA; ATAHC Study Group Second Line Author. Patterns andcharacteristics of hepatitis C transmission clusters among HIV-positive and HIV-negativeindividuals in the Australian trial in acute hepatitis C. Clinical Infectious Diseases 2011;52:803-8112010Poustchi H, Farrell G, Strasser S, McCaughan G, Lee A, George J. Feasibility of conducting arandomised control trial for liver cancer screening: Is a randomised controlled trial for livercancer screening feasible or still needed? Hepatology 2011;54:1998-2004.Mahady S, George J. Adding Flexibility of Physician Training. Medical Journal of Australia2011;194:460-462.Raftopoulos SC, George J, Bourliere M, Rossi E, de Boer WB, Jeffrey GP, Bulsara M, SpeersDJ, MacQuillan G, Ching HL, Kontorinis N, Cheng W, Flexman J, Fermoyle S, Rigby P, WalshL, McLeod D, Adams LA. Comparison of Non-Invasive Models of Fibrosis in Chronic HepatitisB. Hepatology International 2011; (E-pub ahead of print, 12/06/2011).Johnson NA, van Overbeek D, Chapman PG, Thompson MW, Sachinwalla T, George J. Effect ofprolonged exercise and pre-exercise dietary manipulation on hepatic triglycerides in trainedmen. European Journal of Applied Physiology 2012;112:1817-25.Johnson NA, Keating SE, George J. Exercise and the Liver: Implications for therapy in fattyliver disorders. Seminars in Liver Disease 2012;32:1-15.Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega-3 Supplementationand Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Journal ofHepatology 2012;56:944-51.Westmead Millennium Institute

Hebbard L, George J. The Chicken or the Egg: Adipocytes and hepatic insulin resistance. Journalof Clinical Investigation 2010;51:1076-1079. (Re-printed with Permission). Hepatology Elsewhere2010;51:1076-1079. [Abstract]Milner KL, van der Poorten D, Trenell M, Jenkins A, Xu A, Smythe G, Dore G, Zerky A, WeltmanM, Fragomeli V, George J*, Chisholm D*. Chronic hepatitis C Associated insulin resistance ispredominantly peripheral rather than hepatic. Gastroenterology 2010;138:932-941.e3. * Equalsenior author. [Abstract]Media Releases:http://sydney.edu.au/medicine/news/news/2010/Mar/100309.phphttp://www.diabeteshealth.com/read/2010/07/21/6768/hepatitis-c-and-insulin-resistance-/Online Extra – YouTube Discussion with the Authors:http://www.youtube.com/watch?v=sWbF4sQmQMQGrebely J, Petoumenos K, Matthews GV, Haber P, Marks P, Lloyd AR, Kaldor JM, Dore GJ, HellardM; for the ATAHC Study Group. Second Line Author. Factors associated with uptake oftreatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort:The ATAHC Study. Drug and Alcohol Dependence 2010;107:244-249.Pattullo V, George J. The problem of insulin resistance and its effect on therapy. AdvancedTherapy for Hepatitis C Infection 2010, Section 2, Chapter 23 (Submitted 25/01/2010).Johnson NA, George J. An Active Part in Treating Liver Disease. Exercise In Medical Conditions:Exercise And Non-Alcoholic Fatty Liver Disease. SportEX Health 2010;25:18-20. www.sportex.netJohnson NA, George J. Fitness versus fatness: moving beyond weight loss in NAFLD. Hepatology2010; 52:370-381. [Abstract]Robotin M, Kansil M, George J, Howard K, Tipper S, Levy M, Phung N, Penman A. Using aPopulation-Based Approach to Prevent Hepatocellular Cancer in New South Wales, Australia:Effects on Health Services Utilisation. BMC Health Services Research 2010; 10:215. [Abstract] Grebely J, Petounmenos K, Hellard M, Matthews G, Suppiah V, Applegate T, Yeung B, Marks P,Rawlinson W, Lloyd A, Booth D, Kaldor J, George J, Dore G; for the ATAHC Study Group. PotentialRole For IL28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection.Hepatology 2010 (Accepted for publication 9th July 2010) (In Print). [Abstract]Bhala, N, Usherwood, T, George, J. Non-alcoholic fatty liver. Praxis 2010: 187-189 (Published inGerman). [Abstract]Pattullo, V., George, J. (2010),Managing the Patient with Chronic Viral Hepatitis ReceivingChemotherapy. In: When Cancer Crosses Disciplines: A Physician's Handbook. (pp.813-832).London, UK: Imperial College Press. van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J., Ho, V.,Hebbard, L., Douglas, M., George, J. (2010), Hepatitis C virus induces the cannabinoid receptor 1.PloS One. 5, pii: e1284. [Abstract] Mahady, S., George, J. (2010), How to Treat: Hepatitis C infection. Australian Doctor. Feb 2010,1-6.Ahlenstiel, G., Booth, D., George, J. (2010), IL28B in hepatitis C virus infection: translatingpharmacogenomics into clinical practice. Journal of gastroenterology. 45, 903-10. [Abstract]Westmead Millennium Institute

2009Phung N, Pera N, Farrell G, Leclercq I, Hou JY, George J. Pro-oxidant-mediated hepatic fibrosisand effects of antioxidant intervention in murine dietary steatohepatitis. International Journal ofMolecular Medicine 2009;24:171-80. [Abstract]Bhala N, Usherwood T, George J. Non-alcoholic Fatty Liver Disease: 10 Minute Consultation.British Medical Journal 2009;339:b2474. [Abstract] Matthews G; Hellard M; Haber P; Marks P; Baker D; Sasadeusz J; Bloch M; Crawford D;Rawlinson W; Lloyd A; Kaldor J; Dore G. Characteristics And Treatment Outcomes Amongst HivPositive Individuals Within The Australian Trial In Acute Hepatitis C. for the ATAHC Study Group.Second line author. Clinical Infectious Diseases 2009;48:650-658. Author Reply: ClinicalInfectious Diseases 2009;49:319.George J, Robotin M. Overview: Hepatocellular Carcinoma – The Future Starts Now. CancerForum 2009;33:80-87. Wang J, Leclercq I, Brymora JM, Ramezani-Moghadam M, London RM, Brigstock D, George J.Kupffer cells: the main player in leptin- induced liver fibrosis. Gastroenterology 2009;137:713-723. [Abstract]Robotin MC, Kansil M, Howard K, George J, Tipper S, Dore GJ, et al. Antiviral therapy forhepatitis B-related liver cancer prevention is more cost-effective than cancer screening. Journalof Hepatology, 2009;50:990-998 [Abstract]Editorial: Sherman M. Prevention of hepatocellular carcinoma: The holy grail of hepatitis Btreatment. Journal of Hepatology 2009;50:854-856. [Abstract]Analysis: Included in the Tufts Medical Centre Cost-Effectiveness Analysis (CEA) Registry:https://research.tufts-nemc.org/cear/search/detail.aspx?ArticleId=2009-01-05098http://www.cearegistry.org/ Milner K, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KSL, Chisholm DJ, George J.Adipocyte Fatty Acid Binding Protein levels relate to inflammation and fibrosis in Non AlcoholicFatty Liver Disease. Hepatology 2009;49:1926-34. [Abstract]van der Poorten, Milner K, George J, Chisholm D. Adipocyte Levels in Non Alcoholic Fatty LiverDisease. Hepatology 2009;50:327-328. [Letter]Smith B, George J. Adipocyte-hepatocyte Crosstalk and the Pathogenesis of Nonalcoholic FattyLiver Disease. Hepatology 2009;49:1765-1767. [Abstract]Milner K, George J. Sex differences of adipokine expressions and NAFLD patients. FemaleHepatology: Impact of female sex on progression of liver disease 2009 (ISBN:978-81-308-0361-6).Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, McCaughan G, Sasadeusz J, WhiteP, Rawlinson W, Lloyd A, Kaldor J, Dore GJ; Australian Trial in Acute Hepatitis C Study Group.Second Line Author. Characteristics and treatment outcomes among HIV-infected individuals inthe Australian Trial in Acute Hepatitis C. Clinical Infectious Disease 2009;48:650-658.Westmead Millennium Institute

Booth ML, Dobbins T, Aitken R, Denney-Wilson E, Hardy LL, Okely AD, George J, Sullivan D,Cowell C. Costs of Managing Conditions associated with Obesity Among Australian Teenagers.Journal of Paediatrics and Child Health 2009 45:448-56. [Abstract] Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, George J.Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weightloss. Hepatology 2009;50:1105-1112. [Abstract]Exclusive Author Commentary: MedLinx rated number 4: (04/08/2009)http://www.mdlinx.com/endolinx/news-article.cfm/2821227Accepted for Media release: Brooks M. Reuters Health. Exercise, even without weight loss,reduces obesity-related fatty liver. (Published 17th September 2009)Accepted for Media Release: Regular Aerobic Exercise Reduces Health Concerns Associatedwith Fatty Liver. Benefits Are Not Dependent On Weight Loss. Hepatology News Alert.September 2009. Pattullo V, George J. Managing the Patient with Chronic Hepatitis receiving Chemotherapy. InConsultation: When Cancer Crosses Disciplines. Imperial College Press 2010 Chapter 32;813-832. Dore GJ, Hellard M, Matthews G, Grebely J, Harber PS, Petoumenos K, Yeung B, Marks P, vanBeek I, McCaughan G, White P, Ffrench R, Rawlinson W, Lloyd AR, Kaldor JM on behalf of theATAHC Study Group. Second Line Author. Effective treatment of injecting drug users withrecently acquired Hepatitis C virus infection: The ATAHC Study. Gastroenterology 2010;138:123-135.e1-2. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. The Independent Effects ofPhysical Activity in Patients with Non-Alcoholic Fatty Liver Disease. Hepatology 2009;50:68-76.Accepted for Media Release Exercise Helps Patients with Non-Alcoholic Fatty Liver Disease. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a Lifesyle Interventionin Patients with Abnormal Liver Enzymes and Metabolic Risk Factors. Journal ofGastroenterology and Hepatology 2009;24:399-407. [Abstract]Editorial: Hickman I. Obesity management in liver clinics: What’s your style of lifestyleintervention? Journal of Gastroenterology and Hepatology 2009;24:327-328.Douglas MW, George J. Molecular mechanisms of insulin resistance in chronic hepatitis C. WorldJournal of Gastroenterology 2009;15:4356-4364. [Abstract] Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U,Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ,Booth DR, George J for the Hepatitis C Group. IL28B is associated with response to chronichepatitis C interferon-alpha and ribavirin therapy. Nature Genetics 2009;41:1100-1104. Selectedfor Media Release. [Abstract]Editorial: O’Brien TR. Interferon-alpha, interferon-lambda and hepatitis C. Nature Genetics2009;41:1048-1050.Tanaka et al. Genome-wide association of IL28B with response to pegylated interferon-α andribavirin therapy for chronic hepatitis C. Nature Genetics 2009;41:1105-1109.Review: May M. Variant predicts HCV response. Nature Biotechnology 2009;27:964. Review:Borowski C. Picking hepatitis C virus treatment responders. Asia-Pacific International MolecularWestmead Millennium Institute

Biology Network. 2009 (AIMBN).A-IMBN Research Highlights: Genetic analysis provides a means to predict the response ofindividuals to standard treatment for chronic infection with the hepatitis C virus. Asia PacificInternational Molecular Biology Network and Nature Japan K.K (NPG Nature Asia-Pacific) 2009(25/11/2009) http://natureasia.com/A-IMBN/article.php?id=336Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, SchmidtW, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Bedossa P,Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J for the EPIC Study Group.Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferonalfa/Ribavirin Therapy. Second Line Author. Gastroenterology 2009;136:1618-28. 127.van Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D, Bower GD, Briggs GM,Rossleigh MA, Taylor DJ, George J. Treatment of 5-Fluorouracil-Refractory Patients With LiverMetastases From Colorectal Cancer Using Yttrium-90 Resin Microspheres Plus ConcomitantSystemic Irinotecan Chemotherapy. Journal of Clinical Oncology 2009;27:4089-4095. [Abstract]Editorial: Kuebler JP. Radioembolization of Liver Metastases in Patients with Colorectal cancer:A Nonsurgical Treatment With Combined Modality Potential. Journal of Clinical Oncology2009;27:1041-4042. Milner KL, Chisholm D, George J. The Many Faces of Hepatitis C: Liver Disease and Type 2Diabetes. Hepatology 2009;50:668-670. [Editorial] [Abstract] Roberts S, Weltman MD, Crawford D, McCaughan GW, Sievert W, Cheng WS, Rawlinson W,Desmond PV, Marks PS, Yoshihara M, Rizkalla B, DePamphilis JK, Dore G for the Chariot StudyGroup. Impact of High-Dose Peginterferon Alfa-2A on Virological Response Rates in Patientswith Hepatitis C Genotype 1: a Randomized Controlled Trial.Second Line Author Hepatology 2009;50:1045-1055. Mahady S, George J. How To Treat: Hepatitis C Infection. Australian Doctor 2010;2:19-26. George J, Robotin M Editors. Hepatocellular Carcinoma. Cancer Forum. Journal of the ClinicalOncology Society of Australia July 2009; 1-136.2008Poustchi H, Negro F, Hui J, Cua IH, Brandt L, Kench J, George J. Insulin Resistance and Responseto Therapy in Patients Infected with Chronic Hepatitis C Virus Genotype 2 and 3. J Hepatol.2008;48:28-34. [Abstract]Wang J, Brymora J, George J. The roles of adipokines in liver injury andfibrosis. Expert Review in Gastroenterology and Hepatology, 2008;2:47-57. [Abstract]George J, Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclearreceptors as therapeutic targets. Mol Pharm 2008;5:49-59. (Impact Factor 11.03).[Abstract]Robotin M, George J, Supramaniam R, Sitas F, Penman A. Preventing primary livercancer: how well are we faring towards a National Hepatitis B strategy? The Medical Journal ofWestmead Millennium Institute

Australia 2008;188:363-365. Reply Letter to the Editor: Medical Journal of Australia2008;189:237. [Abstract] van der Poorten D, George J. Disease-specific mechanisms of fibrosis – HCV and NASH. Clin LivDis 2008;12:805-24. [Abstract] van der Poorten D, Milner K, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, ChisholmDJ, George J. Visceral fat: A key mediator of steatohepatitis in metabolic liver disease.Hepatology 2008;48:449-57. (Selected for Faculty of 1000 Medicine and evaluated by StefanoBellentani) [Abstract]. van der Poorten D, George J. Nonalcoholic steatohepatitis is frequently accompanied bymetabolic diseases. Reply to the Editor. Hepatology 2008;48:1729. van der Poorten D, Kenny DT, George J. Prevalence of and risk factors for hepatitis C inAboriginal and non-Aboriginal adolescent offenders. MJA 2008;188:610-614. [Abstract] Johnston N, Walton D, Sachinwalla T, Thompson C, Smith K, Ruell PA, Stannard SR, George J.Non-invasive assessment of hepatic lipid composition: advancing understanding andmanagement of fatty liver disorders. Hepatology 2008;47:1513-1523. [Abstract] Poustchi H, Mohamadkhani A, Bowden S, Montazeri G, Ayres A, Revill P, Farrell GC, Locarnini S,George J, Malekzadeh R. Clinical significance of pre-core and core promoter mutations ingenotype D hepatitis B-related chronic liver disease. Journal of Viral Hepatitis 2008;15:753-760.[Abstract] Johnston N, Sachinwalla T, George J. In Vitro Proton Magnetic Resonance Spectroscopy of LiverTissue Informs In Vivo Hepatic Proton Magnetic Resonance Spectroscopy Studies. Reply to theEditor. Hepatology 2008;48:1016-1017. Yan K, Guirgis M, Dinh T, George J, Dev A, Lee A, Zekry A. A Case-Control Study EvaluatingTreatment Responses in Asians and Caucasians with Chronic Hepatitis C Infection. World JGastroenterol 2008;14(21):3416-3420. [Abstract] Cua I, Hui J, Kench J, George J. Genotype-specific interactions of insulin resistance, steatosis andfibrosis in chronic hepatitis C. Hepatology 2008;48:723-731. [Abstract] Booth ML, George J, Denney-Wilson E, Okely AD, Hardy LL, Aitken R, Dobbins T. The populationprevalence of adverse concentrations and associations with adiposity of liver tests amongAustralian adolescents. Journal of Paediatrics and Child Health, 2008;44: 686-91. [Abstract] J. George, Dennny-Wilson E, Okley AD, Hardy LL, Aitken R. The population distributions, uppernormal limits and correlations between liver tests among Australian adolescents. Journal ofPaediatrics and Child Health 2008;44:579-583. [Abstract] St George A, Bauman A, Johnston A, Farrell G, Chen T, George J. Effect of lifestyle intervention inpatients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol 2008(E-Pub ahead of print, accepted 4 December 2008). [Abstract]2007Poustchi H, Negro F, Hui J, Kench J, George J. Insulin resistance and treatment response: role ingenotypes 2 and 3 chronic HCV infection. J Hepatology 2007;48:28-34. [Abstract]Westmead Millennium Institute

Cua IHY, Hui J, Bandara P, Kench J, Farrell G, McCaughan GW and George J. Insulin Resistanceand Liver Injury in Hepatitis C Is Not Associated with Virus-Specific Changes in Adipocytokines.Hepatology 2007;46:66-73. [Abstract]van der Poorten D, Kenny D, Butler T, George J. Liver Disease in Adolescents: A Cohort Study ofHigh-Risk Individuals. Hepatology. 2007 Dec;46(6):1750-8.[Abstract] Razali K, Thein H, Bell J, Cooper-Stanbury M, Dolan K, Dore G, George J, Kaldor J, Karvelas M,Jiong L, Maher L, McGregor S, Hellard M, Poeder F, Quaine J, Stewart K, Tyrell H, Weltman M,Westcott O, Wodak A, Law M. Modelling the hepatitis C virus epidemic in Australia. Drug andAlcohol Dependence [Abstract].Angulo P, Hui J, Marchesini G, Bugianesi E, George J, et al. The NAFLD Fibrosis Score: A simplenon-invasive system that accurately identifies liver fibrosis in patients with non-alcoholic fattyliver disease. Hepatology, 2007;45:846-854. [Abstract] London RM, George J. Pathogenesis of NASH: Animal Models.Clinics in Liver Disease 11 (2007)55-74 [Abstract]2006E. Bugianesi, G. Marchesini, E. Gentilcore, I.H.Y. Cua, E. Vanni, M. Rizzetto, J. George. Fibrosis inGenotype 3 Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease: Role of insulin Resistanceand Hepatic Steatosis. Hepatology 2006;44:1648-1655 [Abstract]Wang, J, Batey, R, George, J. Role of ethanol in the regulation of hepatic stellate cell function.World journal of gastroenterology : WJG. 2006; 12:6926-6932 [Abstract]Cua, I, Kwan, V, Henriquez, M, Kench, J, George, J. Long term suppressive therapy withpegylated interferon for chronic hepatitis C associated membranoproliferativeglomerulonephritis. Gut. 2006; 55:1521-2 [Abstract]Salmond, S, George, J, Strasser, S, Batey, R. Hep573 study of complementary medicine forchronic hepatitis C. Journal of Clinical Virology. 2006; 36:S134-S135 [Abstract] Leandro, G, Mangia, A, Hui, J, Fabris, P, Rubbia-Brandt, L, Colloredo, G, Adinolfi, L, Asselah, T,Jonsson, J, Smedile, A, Terrault, N, Pazienza, V, Giordani, M, Giostra, E, Sonzogni, A, Ruggiero, G,Marcellin, P, Powell, E, George, J, Negro, F, , H. Relationship between steatosis, inflammation,and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology.2006; 130:1636-42 [Abstract]2005George, J. Angiopoietin-like proteins: another player in the metabolic field. Journal ofhepatology. 2006; 44:832-4 [Abstract]Cua IH and George J. Interpretation of abnormal liver tests in patients with diabetes. DiabetesManagement Journal 2006; 14: 30.Westmead Millennium Institute

Dela Peña, A, Leclercq, I, Field, J, George, J, Jones, B, Farrell, G. NF-kappaB activation, ratherthan TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis.Gastroenterology. 2005; 129:1663-74 [Abstract]Adams, L, Bulsara, M, Rossi, E, DeBoer, B, Speers, D, George, J, Kench, J, Farrell, G, McCaughan,G, Jeffrey, G. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis Cinfection. Clinical chemistry. 2005; 51:1867-73 [Abstract]Kumar, D, Farrell, G, Kench, J, George, J. Hepatic steatosis and the risk of hepatocellularcarcinoma in chronic hepatitis C. Journal of gastroenterology and hepatology. 2005; 20:1395-400 [Abstract]Bandara, P, George, J, McCaughan, G, Naidoo, D, Lux, O, Salonikas, C, Kench, J, Byth, K, Farrell,G. Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitisC. Liver international : official journal of the International Association for the Study of the Liver.2005; 25:518-26 [Abstract]Perry, J, Poustchi, H, George, J, Farrell, G, McCaughan, G, Strasser, S. Current approaches to thediagnosis and management of hepatocellular carcinoma. Clinical and experimental medicine.2005; 5:1-13 [Abstract]2004 Kwan, V, George, J. Liver disease due to parenteral and enteral nutrition. Clinics in liver disease.2004; 8:893-913, ix-x [Abstract] Hui, J, Hodge, A, Farrell, G, Kench, J, Kriketos, A, George, J. Beyond insulin resistance in NASH:TNF-alpha or adiponectin?. Hepatology (Baltimore, Md.). 2004; 40:46-54 [Abstract] Sud, A, Hui, J, Farrell, G, Bandara, P, Kench, J, Fung, C, Lin, R, Samarasinghe, D, Liddle, C,McCaughan, G, George, J. Improved prediction of fibrosis in chronic hepatitis C using measuresof insulin resistance in a probability index. Hepatology (Baltimore, Md.). 2004; 39:1239-47[Abstract] Coverdale, S, Khan, M, Byth, K, Lin, R, Weltman, M, George, J, Samarasinghe, D, Liddle, C, Kench,J, Crewe, E, Farrell, G. Effects of interferon treatment response on liver complications of chronichepatitis C: 9-year follow-up study. The American journal of gastroenterology. 2004; 99:636-44[Abstract] Chitturi, S, Farrell, G, George, J. Non-alcoholic steatohepatitis in the Asia-Pacific region: futureshock?. Journal of gastroenterology and hepatology. 2004; 19:368-74 [Abstract] McCaughan, G, George, J. Fibrosis progression in chronic hepatitis C virus infection. Gut. 2004;53:318-21 [Abstract] McCaughan GW and George J. Fibrosis progression in chronic hepatitis C virus infection. Gut2004; 53: 318-321. [Abstract] Hui JM, Farrell GC, Kench JG and George J. High sensitivity C-reactive protein values do notreliably predict the severity of histological change in NAFLD. Hepatology 2004; 39: 1458-1459.[Abstract]Westmead Millennium Institute

Farrell GC, George J, Hall P de La M and McCullough. Overview: An introduction to NASH andrelated fatty liver disorders. In: Fatty Liver Disease: NASH and Related Disorders. 2004, Chapter1: 1-11.George J and Farrell GC. Practical approach to the diagnosis and management of people withfatty liver diseases. In: Fatty Liver Disease: NASH and Related Disorders. 2004, Chapter 15: 181-193.Chitturi S and George J. NAFLD/NASH is not just a ‘Western’ problem: some perspectives onNAFLD/NASH from the East. In: Fatty Liver Disease: NASH and Related Disorders. 2004, Chapter18: 218-228.Kirsch R, Hall P de la M, George J, McCullough AJ and Farrell GC. Recent advances. In: Fatty LiverDisease: NASH and Related Disorders. 2004, Chapter 24: 289-302.Zeuzem S, Diago M, Gane E, Reddy KR, et al. for the PEGASYS Study NR16071 InvestigatorGroup. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis Cand normal aminotransferase levels. Gastroenterology 2004; 127: 1724-1732. [Abstract]2003 Perry, J, Strasser, S, George, J, Farrell, G, McCaughan, G. Pharmacotherapy of hepatocellularcarcinoma. Expert Opinion On Pharmacotherapy. 2003; 4(12):2175-2185. [Abstract] Hui, J, Sud, A, Farrell, G, Bandara, P, Byth, K, Kench, J, McCaughan, G, George, J. Insulinresistance is associated with chronic Hepatitis C and virus infection fibrosis progression.Gastroenterology. 2003; 125:1695-1704 . [Abstract] Kumar, D, Wallington-Beddoe, C, George, J, Lin, R, Samarasinghe, D, Liddle, C, Farrell, G.Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hapatitis c in aclinic setting. Medical Journal Of Australia. 2003; 178:267-271. [Abstract]George, J, Pera, N, Phung, T, Leclercq, I, Hou, J, Farrell, G. Lipid peroxidation, stellate cellactivation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. Journal OfHepatology. 2003; 39:756-764. [Abstract] Coverdale, S, Samarasinghe, D, Lin, R, Kench, J, Byth, K, Khan, M, Crewe, E, Liddle, C, George, J,Farrell, G. Changes in antipyrine clearance and platelet count, but not conventional liver tests,correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression.American Journal Of Gastroenterology. 2003; 98(6):1384-1390. [Abstract]Hui, J, Kench, J, Chitturi, S, Sud, A, Farrell, G, Byth, K, Hall, P, Khan, M, George, J. Long termoutcomes of cirrhosis in nonalcoholic steatohepatitis compares with hepatitis c. Hepatology.2003; 38:420-427. [Abstract]George J. Invited Book Review – Hepatitis C: An Australian perspective. Eds. N Crofts, G Dore andS Locarnini. Internal Medicine J 2003; 33: 64.Teoh N and George J. Letter to the Editor: Alcoholic liver disease: the AST and ALT of it all.Medicine Today 2003, 4: 113 ( see MedicineToday 2002; 3: 58-67).Westmead Millennium Institute

Chitturi, S, Abeygunasekera, S, Farrell, G, Holmes-Walker, J, Hui, J, Fung, D, Karim, R, Lin, R,Samarasinghe, D, Liddle, C, Weltman, M, George, J. NASH and Insulin Resistance: InsulinHypersecretion and Specific Association with the Insulin Resistance Syndrome. Hepatology.2002; 35:373-379. [Abstract] Chitturi, S, Farrell, G, Frost, L, Kriketos, A, Lin, R, Liddle, C, Samarasinghe, D, George, J. Serumleptin in NASH correlates with hepatic steatosis but not fibrosis: a mnifestation of lipotoxicity?.Hepatology. 2002; 36:403-409. [Abstract] Wong, V, Fu, A, George, J, Cheung, N. Two forms of thyrotoxicosis induced by alpha-interferontherapy in the treatment of chronic viral hepatitis. Clinical Endocrinology. 2002; 56:793-798.[Abstract] Singal D K and George J. Chronic hepatitis C. Australian Doctor 15 February2002.Farrell GC,Robertson G, Leclercq I, George J, Weltman M, Liddle C. Inducible cytochromes P450 and lipidperoxidation in NASH (NASH 2000). Teoh N and George J. Evaluating patients who have abnormal liver tests. Invited Review.MedicineToday 2002; 3: 58-67. (See also Letter to the Editor Medicine Today 2003, 4: 113.).2001 Chitturi, S, Hui, J, Salisbury, E, Mitchell, D, George, J. Abdominal pain in an intrauterinecontraceptive devise user. Postgraduate Medical Journal. 2001; 42 (3):253-266. [Abstract] Phung, N, Farrell, G, Robertson, G, George, J. Antioxidant therapy with vitamin E ameliorateshepatic fibrosis in MCDD-associated NASH. Journal of Gastroenterology and Hepatology. 2001;33:248-251 Chitturi, S, Abeygunasekera, S, Fung, C, Samarasinghe, D, Lin, R, McDonald, D, Weltman, M,Farrell, G, George, J. Haemochromatosis gene mutations, hepatic iron content and nonalcoholicsteatohepatitis. Hepatology. 2001; 19:1768-1778 Leclercq, I, Field, J, George, J, Farrell, G, Robertson, G. Leptin is an essential mediator of hepaticfibrogenesis and liver regeneration in chronic CCl4-induced liver injury. Journal ofGastroenterology and Hepatology. 2001; 24:51-59Pera, N, Phung, N, Leclercq, I, Farrell, G, George, J. Oxidative stress and the evolution of hepaticfibrogenesis in a rodent model of nonalcoholic steatohepatitis. Journal of Gastroenterology andHepatology. 2001; 21:140-151 Coverdale, S, Samarasinghe, D, Lin, R, Kench, J, Byth, K, Khan, M, Crewe, E, Liddle, C, George, J,Farrell, G. Prediction of histological progression in chronic hepatitis C. Journal ofGastroenterology and Hepatology. 2001; 10:182-189George, J, Hui, J, Farrell, G, Kench, J, Lin, R, Samarasinghe, D. Predictors fo rsteatosis and fibrosisin chronic hepatitis C. Journal of Hepatology. 2001; 12:365-371George, J, Hui, J, Farrell, G, Kench, J, Lin, R, Samarasinghe, D, Liddle, C. Predictors for steatosisand fibrosis in chronic hepatitis C. Journal of Hepatology. 2001; 35:822-826Westmead Millennium Institute

Chitturi, S, Frost, L, Farrell, G, Liddle, C, Samarasinghe, D, Lin, R, George, J. Serum Leptin: Anindependent predictor of hepatic steatosis but not fibrotic severity in nonalcoholicsteatohepatitis. Hepatology. 2001; 174:271-275 Pera, N, Phung, N, Leclercq, I, Farrell, G, George, J. The role of oxidative stress in the evolution ofhepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. Hepatology. 2001;54:624-630 Pera, N, Phung, N, Leclercq, I, Farrell, G, George, J. This role of oxidative stress in the evolutionof hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. Hepatology. 2001;35:756-764 Bissell, D, Roulot, D, George, J. Transforming growth factor B and the liver. Hepatology. 2001;21:27-40 Phung, N, Farrell, G, Robertson, G, George, J. Vitamin E but not glutathione precursorsameliorates hepatic fibrosis in experimental NASH. Journal of Gastroenterology and Hepatology.2001; 71:403-406 Phung, N, Farrell, G, Robertson, G, George, J. Vitamin E but not glutathione precursors inhibitshepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrialabnormalities. Hepatology. 2001; 14(5):1070-1079 Phung, N, Farrell, G, Robertson, G, George, J. Vitamin E but not gluthathione precursorsameliorates hepatic fibrosis in experimental NASH. Journal of Gastroenterology and Hepatology.2001; 25:242-2462000 George, J. Biochemical markers of hepatic fibrogenesis: single measurements are not reliableenough to replace liver biopsy. Journal of Gastroenterology and Hepatology. 2000; 15:819-821 Chitturi, S, George, J. Predictors of liver-related complications in patients with chronic hepatitisC. Annals of Medicine. 2000; 32:588-591 George, J, Wang, S, Sevcsik, A, Sanicola, M, Cate, R, Koteliansky, V, Montgomery Bissell, D.Transforming growth factor-B initiates wound repair in rat liver through induction of the EIIIAfibronectinsplice isoform. American Journal of Pathology. 2000; 156:115-124 Khan, M, Farrell, G, Byth, K, Lin, R, Weltman, M, George, J, Samarasinghe, D, Kench, J, Kaba, S,Crewe, E, Liddle, C. Which patients with hepatitis C develop liver complications. Hepatology.2000; 31:513-520.Westmead Millennium Institute